This work is licensed under a Table 3.
Serum concentrations of cytokines (pg/mL) among patients with thyroid-stimulating hormone (TSH) concentrations ≥0.4 and <0.4 mIU/L.
| TSH ≥ 0.4 mIU/L (n = 103) | TSH < 0.4 mIU/L (n = 13) | P-value | |
|---|---|---|---|
| IL-1α, median (IQR) | 16 (12–20) | 15 (10–18) | 0.575 |
| IL-1β, median (IQR) | 9.5 (7–12) | 8 (6–10) | 0.120 |
| IL-1ra, median (IQR) | 2843 (1689–5146) | 3262 (2017–4634) | 0,857 |
| IL-2, median (IQR) | 4 (3–5) | 4 (3–5) | 0.973 |
| IL-6, median (IQR) | 76 (37–166) | 91 (71–171) | 0.204 |
| IL-7, median (IQR) | 12 (9–16) | 13 (9–21) | 0.678 |
| IL-8, median (IQR) | 39 (23–56) | 61 (39–79) | 0.011 |
| IL-10, median (IQR) | 277 (173–364) | 357 (294–423) | 0.052 |
| IL-12, median (IQR) | 22 (22–22) | 22 (22–22) | 0.366 |
| IL-15, median (IQR) | 4 (3–5) | 5 (4–9) | 0.053 |
| IL-33, median (IQR) | 17 (13–22) | 21 (17–22) | 0.116 |
| IFN-α, median (IQR) | 7 (7–7) | 7 (7–7) | 0.586 |
| IFN-γ, median (IQR) | 4 (4–13) | 4 (4–6) | 0.942 |
| TNF-α, median (IQR) | 13 (13–18) | 14 (13–25) | 0.143 |
| CD40, median (IQR) | 4.8 (3–7) | 4.5 (3–6) | 0.398 |
| MCP-1, median (IQR) | 765 (570–1093) | 881 (769–1850) | 0.086 |
| MIP-1α, median (IQR) | 5 (5–11) | 11 (5–24) | 0.182 |
| MIP-1β, median (IQR) | 409 (350–470) | 436 (353–537) | 0.333 |
| MIP-3α, median (IQR) | 21 (14–35) | 29 (14–56) | 0.434 |
| MIP-3β, median (IQR) | 203 (149–363) | 293 (179–381) | 0.187 |
| RANTES, median (IQR) | 30295 (20468–50512) | 40530 (33809–52323) | 0.166 |
| Eotaxin, median (IQR) | 222 (170–270) | 283 (192–347) | 0.235 |
| GRO-α, median (IQR) | 220 (157–344) | 216 (207–301) | 0.580 |
| GRO-β, median (IQR) | 1663 (1239–2668) | 2280 (1789–2689) | 0.131 |
| IP-10, median (IQR) | 957 (439–1760) | 1760 (1004–2359) | 0.042 |
| EGF, median (IQR) | 214 (147–298) | 221 (183–300) | 0.722 |
| Flt-3 ligand, median (IQR) | 125 (99–149) | 130 (101–153) | 0.532 |
| G-CSF, median (IQR) | 62 (49–76) | 54 (49–77) | 0.480 |
| GM-CSF, median (IQR) | 115 (74–134) | 136 (133–156) | 0.019 |
| Granzyme B, median (IQR) | 15 (6–22) | 19 (5–39) | 0.381 |
| PD-L1, median (IQR) | 185 (133–235) | 304 (121–338) | 0.268 |
| PDGF-AA, median (IQR) | 5170 (5170–5170) | 5170 (5170–5170) | 0.846 |
| PDGF-AB/BB, median (IQR) | 3181 (2091–4852) | 2698 (2142–4093) | 0.369 |
| TRAIL, median (IQR) | 32 (23–51) | 29 (23–33) | 0.381 |
| VEGF, median (IQR) | 419 (295–650) | 452 (347–614) | 0.172 |
CD, cluster differentiation; FGF basic, fibroblast growth factor; Flt-3 ligand, Fms-like tyrosine kinase-3 ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; Granzyme B, granule enzyme B; GRO-α, growth regulated oncogene-α; GRO-β, growth regulated oncogene-β; IFN, interferon; IL, interleukin; IP-10, interferon-inducible protein 10; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; PDGF-AA, platelet-derived growth factor-AA; PDGF-AB/BB, platelet-derived growth factor-AB/BB; PD-L1, programmed death-1 ligand 1; RANTES, regulated upon activation normal T-cell expressed, and presumably secreted; TGF-α, transforming growth factor-α; TNF, ligand superfamily member 5; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis inducing ligand; TSH, thyroid-stimulating hormone; VEGF, vascular endothelial growth factor.